Immunicon now on OTCBB
Immunicon (Huntingdon Valley, Pennsylvania) said that its common stock began quotation on the Over-the-Counter Bulletin Board (OTCBB). Previously, Immunicon had received notification from Nasdaq indicating that trading in the company's common stock would be suspended and delisted from the Nasdaq Capital Market at the opening of business on April 29, unless Immunicon appealed Nasdaq's determination.
In response, Immunicon notified Nasdaq that it would not submit such a plan but would pursue quotation on the OTCBB. Immunicon makes cell- and molecular-based diagnostic and life science research products.
OncoVista eyes pre-IDE for AdnaTest
OncoVista Innovative Therapies (San Antonio, Texas), a biopharmaceutical company specializing in targeted cancer therapies, reported the submission of a request to FDA for a pre-IDE determination meeting for its AdnaGen AdnaTest breast cancer device for the detection of circulating breast tumor cells.
CEO Alexander Weis, PhD, said, "The AdnaTest is intended for use as a prognostic test for women with metastatic breast cancer, in whom the presence of circulating tumor cells is associated with decreased progression-free survival and decreased overall survival and as such can be of tremendous benefit in determining those patients who can best benefit from a certain line of chemotherapy treatment. We look forward to working with the FDA to reach agreement on the design and evaluation criteria for a pivotal study for FDA approval."